Last reviewed · How we verify
GM-CSF priming
GM-CSF priming enhances immune cell activation and recruitment by stimulating granulocyte-macrophage colony-stimulating factor signaling to prime myeloid cells for improved anti-tumor immunity.
GM-CSF priming enhances immune cell activation and recruitment by stimulating granulocyte-macrophage colony-stimulating factor signaling to prime myeloid cells for improved anti-tumor immunity. Used for Cancer immunotherapy priming (phase 3 investigational).
At a glance
| Generic name | GM-CSF priming |
|---|---|
| Sponsor | Eastern Cooperative Oncology Group |
| Drug class | Cytokine immunomodulator |
| Target | GM-CSF receptor (CD116/CD131) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
GM-CSF (granulocyte-macrophage colony-stimulating factor) is a cytokine that promotes the differentiation, proliferation, and activation of myeloid cells including neutrophils, macrophages, and dendritic cells. Priming with GM-CSF before other immunotherapies or treatments aims to enhance the immunogenicity of the tumor microenvironment and improve the efficacy of subsequent immune-mediated anti-tumor responses.
Approved indications
- Cancer immunotherapy priming (phase 3 investigational)
Common side effects
- Fever
- Fatigue
- Injection site reactions
- Bone pain
- Leukocytosis
Key clinical trials
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (PHASE1)
- A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (PHASE1)
- SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (PHASE2)
- Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (PHASE1)
- Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML (PHASE1)
- Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma (PHASE1)
- AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer (PHASE2)
- A Phase 2 Trial for Patients With Metastatic Solid Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |